Dr. Park on Considerations of CAR T-Cell Therapy in Relapsed/Refractory ALL

Video

Jae Park, MD, discusses considerations for CAR T-cell therapy in relapsed/refractory acute lymphoblastic leukemia.

Jae Park, MD, a hematologist oncologist at Memorial Sloan Kettering Cancer Center, discusses considerations for CAR T-cell therapy in relapsed/refractory acute lymphoblastic leukemia (ALL).

Several factors should be taken into account when considering CAR T-cell therapy for patients with ALL, says Park.

​Patients should be consulted early on regarding their eligibility for CAR T-cell therapy, ​Park explains. Then, optimizing bridging therapy ​is necessary to ensure patients have the best chance of deriving benefit from CAR T-cell therapy. 

Patients are encouraged to reach out regarding any questions they may have as a lot of preparation is involved ​prior to CAR T-cell administration, Park explains. 

In addition, clinical trials can be recommended to eligible patients​ as ALL remains a rare disease, Park concludes. 

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira, and Kilian Guse, PhD, the vice president of genetic medicine platforms at Pacira
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira
Jeffrey Chamberlain, PhD
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Related Content
© 2025 MJH Life Sciences

All rights reserved.